{"id":11448,"date":"2024-10-30T15:29:44","date_gmt":"2024-10-30T08:29:44","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=11448"},"modified":"2024-10-30T15:29:44","modified_gmt":"2024-10-30T08:29:44","slug":"teijin-and-hilleman-laboratories-to-expand-business-in-asia-pacific-via-strategic-partnership-to-promote-cdmo-services-in-cell-and-gene-therapy","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=11448","title":{"rendered":"Teijin and Hilleman Laboratories to Expand Business in Asia-Pacific via Strategic Partnership to Promote CDMO Services in Cell and Gene Therapy"},"content":{"rendered":"

SINGAPORE<\/span><\/span>, Oct. 30, 2024<\/span><\/span> \/PRNewswire\/ —\u00a0Teijin Limited<\/a> and Hilleman Laboratories<\/a>, a biotechnology company based in Singapore<\/span>, announced today the signing of a Memorandum of Understanding, for the establishment of a strategic international business partnership. The goal of this partnership is to promote the expansion in contract development and manufacturing organization (CDMO) business in the field of cell and gene therapy.<\/p>\n

\n

\"Memorandum <\/a>
Memorandum of Understanding signing ceremony by Dr. Raman Rao (CEO, Hilleman Laboratories) and Dr. Takayuki Nakano (General Manager, Regenerative Medicine & Implantable Medical Devices, Teijin) (center), joined by representatives from Hilleman Laboratories Singapore and Teijin Group<\/span><\/p>\n<\/div>\n

Under this partnership, Teijin and Hilleman Laboratories will leverage their individual strengths to foster greater synergy for the development and manufacturing of cell and gene therapy products, and mutually advance CDMO business activities of respective parties.<\/p>\n

The partnership was formed to strengthen support for Japanese customers aiming to expand into the Asia-Pacific<\/span> region and to attract overseas customers from Singapore<\/span> and surrounding areas to the Japanese market. Further, Teijin and Hilleman Laboratories share a vision for building a support system in Singapore<\/span> for the development and manufacturing of cell and gene therapies.<\/p>\n

In November 2023<\/span>, Hilleman Laboratories launched its newest facility, a 30,000 square foot current Good Manufacturing Practice (cGMP) pilot-scale plant. Building upon this, Teijin will support Hilleman Laboratories in the establishment of a cell processing center in Singapore<\/span> for cell and gene therapy. Teijin’s accumulated knowledge and experience in this field will be shared with Hilleman Laboratories.<\/p>\n

“Teijin and Hilleman Laboratories are contributing to the provision of innovative medical care through manufacturing,” said Takayuki Nakano<\/span>, Ph.D., Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited. “And we will build a strong cooperation system for the cell and gene therapy CDMO business to provide more desirable development and manufacturing support services to customers in the Asia-Pacific<\/span> region.”<\/p>\n

Teijin group will invest in facilities and human resources to meet customer needs, with a goal of generating JPY 20 billion<\/span> in regenerative medicine sales by FY 2030. The partnership with Hilleman Laboratories will help achieve this goal.<\/p>\n

“At Hilleman Laboratories, we are driven by our mission to deliver impactful healthcare solutions” said Raman Rao<\/span>, Chief Executive Officer of Hilleman Laboratories. “This partnership with Teijin marks a significant milestone in Hilleman Laboratories’ journey to expand our capabilities in bioprocessing. By combining our expertise with Teijin’s leadership in regenerative medicine, we are pushing the boundaries of innovation to develop cutting-edge solutions. This collaboration opens new opportunities for innovation and growth, enabling us to meet the evolving needs of the global healthcare market and positioning Singapore<\/span> as a hub for the next generation of advanced therapeutic products.”<\/p>\n

Demand for CDMO services in cell and gene therapies, including regenerative medicines, is rising due to heightened technical levels in manufacturing and greater specialization in manufacturing and development functions. The fast-growing regenerative medicine market in Japan<\/span> is forecast to exceed JPY 850 billion<\/span> in 2030. This trend is expected to result in a greater number of regenerative medicine products that originate outside Japan<\/span>. For this reason, it is vital to create a system that connects development demand within and outside Japan<\/span>.<\/p>\n

Teijin has established a comprehensive CDMO platform that provides everything from product design to industrialization for regenerative medicine products, focusing on cell and gene therapy. This platform leverages the product launch experience, technical capabilities and knowledge of Japan Tissue Engineering Co., Ltd.<\/a>(J-TEC), a Teijin Group company, and the advanced research, development and production system of Teijin Regenet Co., LTD.<\/p>\n

Hilleman Laboratories, established in 2009 as a joint venture between Merck Sharp & Dohme LLC (MSD) and the Wellcome Trust, aims to make vaccines and biologics affordable in low- and middle-income countries. \u00a0Hilleman Laboratories operates a dual-feature development and manufacturing hub, which provides comprehensive end-to-end biopharmaceutical product development solutions, from concept to the pilot manufacturing of clinical trial materials (CTM) for phase I and II clinical studies.<\/p>\n

About the Teijin Group
<\/b>Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan’s<\/span> first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people in 20 countries. Through “Human Chemistry, Human Solutions,” Teijin relentlessly strives to aims to be a company that supports the society of the future by protecting the global environment and addressing the needs of people and communities. Teijin posted consolidated sales of JPY 1,032.8 billion<\/span> (USD 6.6 billion<\/span>) and total assets of JPY 1,251.0 billion<\/span> (USD 8.0 billion<\/span>) in the fiscal year ending March 31, 2024<\/span>.<\/p>\n

Visit www.teijin.com<\/a>.<\/p>\n

About the <\/b>Hilleman Laboratories
<\/b>Hilleman Laboratories was established in 2009 as a joint venture between Merck Sharp & Dohme LLC (MSD), a global research-driven pharmaceutical company, and Wellcome, a global charitable foundation dedicated to human and animal health. Hilleman Laboratories’ mission is to develop affordable vaccines and biologics against infectious diseases that affect low- and middle-income countries.<\/p>\n

The company’s expertise in end-to-end product development is targeted at creating novel vaccines and biologics in areas of high unmet need as well as adapting existing vaccines and biologics with more effective delivery tools to meet challenging environments in developing countries. Hilleman Laboratories also seeks to collaborate with local, regional, and global partners and stakeholders, including policymakers and governments, to facilitate wider, affordable access to life-saving vaccines and biologics.<\/p>\n

Visit www.hilleman-labs.org<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SINGAPORE<\/span><\/span>, Oct. 30, 2024<\/span><\/span> \/PRNewswire\/ —\u00a0Teijin Limited<\/a> and Hilleman Laboratories<\/a>, a biotechnology company based in Singapore<\/span>, announced today the signing of a Memorandum of Understanding, for the establishment of a strategic international business partnership. The goal of this partnership is to promote the expansion in contract development and manufacturing organization (CDMO) business in the field of cell and gene therapy.<\/p>\n

\n

\"Memorandum <\/a>
Memorandum of Understanding signing ceremony by Dr. Raman Rao (CEO, Hilleman Laboratories) and Dr. Takayuki Nakano (General Manager, Regenerative Medicine & Implantable Medical Devices, Teijin) (center), joined by representatives from Hilleman Laboratories Singapore and Teijin Group<\/span><\/p>\n<\/div>\n

Under this partnership, Teijin and Hilleman Laboratories will leverage their individual strengths to foster greater synergy for the development and manufacturing of cell and gene therapy products, and mutually advance CDMO business activities of respective parties.<\/p>\n

The partnership was formed to strengthen support for Japanese customers aiming to expand into the Asia-Pacific<\/span> region and to attract overseas customers from Singapore<\/span> and surrounding areas to the Japanese market. Further, Teijin and Hilleman Laboratories share a vision for building a support system in Singapore<\/span> for the development and manufacturing of cell and gene therapies.<\/p>\n

In November 2023<\/span>, Hilleman Laboratories launched its newest facility, a 30,000 square foot current Good Manufacturing Practice (cGMP) pilot-scale plant. Building upon this, Teijin will support Hilleman Laboratories in the establishment of a cell processing center in Singapore<\/span> for cell and gene therapy. Teijin’s accumulated knowledge and experience in this field will be shared with Hilleman Laboratories.<\/p>\n

“Teijin and Hilleman Laboratories are contributing to the provision of innovative medical care through manufacturing,” said Takayuki Nakano<\/span>, Ph.D., Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited. “And we will build a strong cooperation system for the cell and gene therapy CDMO business to provide more desirable development and manufacturing support services to customers in the Asia-Pacific<\/span> region.”<\/p>\n

Teijin group will invest in facilities and human resources to meet customer needs, with a goal of generating JPY 20 billion<\/span> in regenerative medicine sales by FY 2030. The partnership with Hilleman Laboratories will help achieve this goal.<\/p>\n

“At Hilleman Laboratories, we are driven by our mission to deliver impactful healthcare solutions” said Raman Rao<\/span>, Chief Executive Officer of Hilleman Laboratories. “This partnership with Teijin marks a significant milestone in Hilleman Laboratories’ journey to expand our capabilities in bioprocessing. By combining our expertise with Teijin’s leadership in regenerative medicine, we are pushing the boundaries of innovation to develop cutting-edge solutions. This collaboration opens new opportunities for innovation and growth, enabling us to meet the evolving needs of the global healthcare market and positioning Singapore<\/span> as a hub for the next generation of advanced therapeutic products.”<\/p>\n

Demand for CDMO services in cell and gene therapies, including regenerative medicines, is rising due to heightened technical levels in manufacturing and greater specialization in manufacturing and development functions. The fast-growing regenerative medicine market in Japan<\/span> is forecast to exceed JPY 850 billion<\/span> in 2030. This trend is expected to result in a greater number of regenerative medicine products that originate outside Japan<\/span>. For this reason, it is vital to create a system that connects development demand within and outside Japan<\/span>.<\/p>\n

Teijin has established a comprehensive CDMO platform that provides everything from product design to industrialization for regenerative medicine products, focusing on cell and gene therapy. This platform leverages the product launch experience, technical capabilities and knowledge of Japan Tissue Engineering Co., Ltd.<\/a>(J-TEC), a Teijin Group company, and the advanced research, development and production system of Teijin Regenet Co., LTD.<\/p>\n

Hilleman Laboratories, established in 2009 as a joint venture between Merck Sharp & Dohme LLC (MSD) and the Wellcome Trust, aims to make vaccines and biologics affordable in low- and middle-income countries. \u00a0Hilleman Laboratories operates a dual-feature development and manufacturing hub, which provides comprehensive end-to-end biopharmaceutical product development solutions, from concept to the pilot manufacturing of clinical trial materials (CTM) for phase I and II clinical studies.<\/p>\n

About the Teijin Group
<\/b>Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan’s<\/span> first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people in 20 countries. Through “Human Chemistry, Human Solutions,” Teijin relentlessly strives to aims to be a company that supports the society of the future by protecting the global environment and addressing the needs of people and communities. Teijin posted consolidated sales of JPY 1,032.8 billion<\/span> (USD 6.6 billion<\/span>) and total assets of JPY 1,251.0 billion<\/span> (USD 8.0 billion<\/span>) in the fiscal year ending March 31, 2024<\/span>.<\/p>\n

Visit www.teijin.com<\/a>.<\/p>\n

About the <\/b>Hilleman Laboratories
<\/b>Hilleman Laboratories was established in 2009 as a joint venture between Merck Sharp & Dohme LLC (MSD), a global research-driven pharmaceutical company, and Wellcome, a global charitable foundation dedicated to human and animal health. Hilleman Laboratories’ mission is to develop affordable vaccines and biologics against infectious diseases that affect low- and middle-income countries.<\/p>\n

The company’s expertise in end-to-end product development is targeted at creating novel vaccines and biologics in areas of high unmet need as well as adapting existing vaccines and biologics with more effective delivery tools to meet challenging environments in developing countries. Hilleman Laboratories also seeks to collaborate with local, regional, and global partners and stakeholders, including policymakers and governments, to facilitate wider, affordable access to life-saving vaccines and biologics.<\/p>\n

Visit www.hilleman-labs.org<\/a><\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-11448","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/11448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11448"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/11448\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}